<DOC>
	<DOCNO>NCT01459718</DOCNO>
	<brief_summary>The primary efficacy endpoint interventional study evaluate number patient achieve complete response ( CR ) , define patient switch intensive deferasirox -DFO treatment , time point 24 month study , deferasirox monotherapy base improvement cardiac magnetic resonance imaging ( MRI ) T2* value &gt; 10ms , continue maintain MRI T2* value &gt; 10 msec .</brief_summary>
	<brief_title>Safety Efficacy Deferasirox Combination With Desferoxamine β-thalassaemia Patients With Severe Cardiac Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Male female patient βthalassemia major , least 18 year old , give write consent participate study . Cardiac MRI T2* value range &lt; =4 &lt; =10 ms. LVEF ≥ 56 % determined CMR . Patients LIC &gt; 10mg Fe/g dw include protocol . Study evaluate first 10 patient 6 month , safety signal present , patient LIC &gt; 5 mg Fe/g dw allow include . Prior iron chelation treatment DFO , DFP , DFX combination DFODFP Patients symptom cardiac dysfunction symptom ( shortness breath rest exertion , orthopnea , exercise intolerance , low extremity edema , arrhythmia ) . Patients cardiac T2* MRI &lt; 4 &gt; 10 m . Patients compliant intensive iron chelation therapy regimens i.v DFO 24 hr infusion DFODFP combination . Patients document liver failure ( presence portal hypertension , hepatic edema , ascites ) . Patients unable undergo study assessment , include blood sampling , MRI , e.g. , claustrophobic MRI , pacemaker , ferromagnetic metal implant approve safe use MRI scanner ( e.g. , type aneurysm clip , shrapnel proximity vital organ retina ) , obese ( exceed equipment limit ) . Patients serum creatinine &gt; ULN significant proteinuria indicate urinary protein/creatinine ratio ≥ 1.0 nonfirst void urine sample baseline.Patients creatinine clearance &lt; 60 ml/min exclude . Patients ALT ( SGPT ) level &gt; 5 x ULN . Patients considerable impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption oral deferasirox / ICL670 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection . History clinical evidence pancreatic injury pancreatitis . Patients know hypersensitivity study drug drug 's excipients . History clinically relevant ocular and/or auditor toxicity relate iron chelation therapy . Patients psychiatric addictive disorder prevent give inform consent undergo treatment option patient unwilling unable comply protocol . Patients known history HIV seropositivity ( Elisa Western blot ) . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Female patient pregnant breast feed . Female patient reproductive potential employ effective method birth control . Women childbearing potential must negative serum pregnancy test ≤ 48 hour prior study drug . Patients participate another clinical trial receive investigational drug . History noncompliance medical regimen patient consider potentially unreliable and/or cooperative , unwilling unable comply protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Severe cardiac iron overload</keyword>
	<keyword>deferasirox</keyword>
	<keyword>β-thalassaemia</keyword>
	<keyword>cardiac dysfunction</keyword>
</DOC>